Investigation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dosing of NNC0174-0833 in Subjects With Obesity or Overweight.
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 20 Oct 2017
At a glance
- Drugs NNC 0174 0833 (Primary)
- Indications Obesity
- Focus Adverse reactions
- Sponsors Novo Nordisk
- 13 Oct 2017 Planned primary completion date changed from 7 Dec 2017 to 24 Jan 2018.
- 13 Oct 2017 Status changed from recruiting to active, no longer recruiting.
- 26 Sep 2017 Planned number of patients changed from 84 to 96.